Together towards a common goal: REVIVE, a community of antimicrobial researchers brought together by the Global Antibiotic Research & Development Partnership (GARDP)

Astrid Pentz-Murr* and Laura J. V. Piddock

Global Antibiotic Research & Development Partnership (GARDP), c/o Drugs for Neglected Diseases initiative, 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland

*Corresponding author. Tel: +41 22 907 76 29; E-mail: apentz-murr@dndi.org

The Global Antibiotic Research & Development Partnership (GARDP) has launched a project, REVIVE, to connect and support the antimicrobial research and development (R&D) community. REVIVE’s educational activities include a webinar series and presentations at key conferences. REVIVE also aims to connect antimicrobial researchers with each other and with current and retired experts in the field, and to develop a comprehensive repository of relevant resources for the R&D community.

The Global Antibiotic Research & Development Partnership (GARDP; https://www.gardp.org) is a not-for-profit research and development (R&D) organization that addresses global public health needs by developing and delivering new or improved antimicrobial treatments, while endeavouring to ensure that access to them is sustainable. Initiated by the WHO and the Drugs for Neglected Diseases initiative (DNDi), GARDP is an important element of the WHO’s Global Action Plan on Antimicrobial Resistance, which calls for new public–private partnerships to encourage research and development of new antimicrobial agents and diagnostics.

It has been often discussed that there is a ‘discovery void’ in the development of antibiotics; many companies have left the field and many researchers have changed their field of work or retired. This is a loss to the community, with valuable experience and knowledge at risk of being lost forever. Ironically, while today’s technology can better connect researchers, working in a research field with a steady personnel turnover and loss of lifetime experts has left new antimicrobial R&D researchers isolated. With this in mind, GARDP created REVIVE to support and connect the antimicrobial R&D community, facilitate learning and share knowledge, and in January 2018 launched the website REVIVE (https://revive.gardp.org).

REVIVE’s aim is to improve, accelerate and streamline antimicrobial drug discovery and R&D by connecting researchers directly with both established and retired antimicrobial researchers and developers. To preserve their knowledge and to make it accessible to other researchers, REVIVE’s expert group comprises those with a track record in antimicrobial discovery and R&D. REVIVE provides those in academia, start-up and biotech companies in the field with access to scientific advice from highly experienced drug developers. Those working on antimicrobials can engage with the REVIVE expert group via the website’s ‘Talk to an expert’ interface (https://revive.gardp.org/talk-to-an-expert). Thus, REVIVE provides a forum for exchange between early-career researchers, drug developers experienced in other disease areas now refocusing their research to address the antimicrobial resistance (AMR) crisis, and clinical and non-clinical researchers. To date, 91 experts have committed to support REVIVE and this number is continuously growing. GARDP is happy to consider additional experts.

REVIVE has a strong educational focus. The REVIVE webinar series was launched in June 2018 and so far four webinars have been held. In the first webinar, David Shlaes discussed traditional development pathways for antimicrobial drugs (https://revive.gardp.org/clinical-development-1). In the second, William Hope gave insights on the pharmacokinetics and pharmacodynamics of antimicrobials (https://revive.gardp.org/pk-pd-in-support-of-accelerated-programmes-for-antimicrobial-development). The third webinar was a panel discussion about the development of antibiotics targeting specific pathogens, with Ian Friedland, Sumathi Nambiar, Mair Powell and David Shlaes (https://revive.gardp.org/clinical-development-2-specific-pathogens/). In the last webinar of 2018, Claire Sadler answered audience questions following the viewing of her presentation ‘Making Safety a Part of Drug Design’ recorded at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2018 (https://revive.gardp.org/making-safety-a-part-of-drug-design/). All webinar presentations were followed by extensive question-and-answer sessions with the audience. More webinars will follow in 2019 (https://revive.gardp.org/category/webinars).

In addition to these virtual events, GARDP is also co-organizing conference sessions with other organizations, including the BSAC and CARB-X, at conferences including ECCMID and ASM Microbe. As a not-for-profit organization with a global scope, GARDP makes...
recordings of its conference sessions available free of charge on the REVIVE website.

The latest addition to REVIVE has been the REVIVE Blog, which aims to share knowledge and stimulate discussions on topics relevant to AMR. The blog was launched in November 2018 with a post by guest author Lord Jim O’Neill on economic models for antimicrobial drug development (https://revive.gardp.org/more-than-one-model-to-stimulate-antimicrobial-drug-development/).

REVIVE also aims to provide a comprehensive repository of relevant resources for antimicrobial researchers. The focus of these resources is freely available, open-access information.

GARDP is working with other organizations to identify existing resources and welcomes suggestions for new resources.

In summary, REVIVE is a space for the antimicrobial R&D community to connect and exchange information. It is GARDP’s vision for REVIVE to grow with the community, in collaboration with all participants, from early-career researchers to seasoned experts, in order to meet their needs. Therefore, we ask readers to work with GARDP on REVIVE.

Transparency declarations

None to declare.